Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Clin Endocrinol (Oxf). 2021 Feb 22;94(6):1043–1053. doi: 10.1111/cen.14426

TABLE 3.

Cardiac events by LMNA pathogenic variant

Odds Ratio (95% CI); P value Odds Ratio (95% CI); P value *
LMNA variant compared to non-LMNA
 Arrhythmia 2.93 (1.29–6.64); 0.010 3.77 (1.45–9.83); 0.007
 Atrial fibrillation/ Atrial flutter 5.30 (1.11–25.39); 0.037 5.78 (1.04–32.16); 0.045
 Conduction abnormality 1.90 (0.70–5.17); 0.211 2.20 (0.71–6.85); 0.173
Odds Ratio (95% CI); p value Odds Ratio (95% CI); P value
Non-482 LMNA variant compared to 482
 Arrhythmia 3.37 (1.12–10.08); 0.030 4.74 (1.41–15.98); 0.012
 Atrial fibrillation/ Atrial flutter 5.44 (1.24–23.95); 0.025 17.67 (2.45–127.68); 0.004
 Conduction abnormality 3.77 (1.05–13.57); 0.042 5.71 (1.37–23.76); 0.017
*

Adjusted for age at cardiac examination, BMI, comorbidities. Sex distribution and diabetes were not included in the model since >85% are diabetics and >80% are females. In addition, sex distribution was not different between LMNA and non-LMNA group, and the sample size did not allow for extra parameters in the model. Seven patients with no complete gene sequencing for LMNA are excluded.

Adjusted only for age at cardiac examination due to limited sample size. Seven patients with no complete gene sequencing for LMNA are excluded.